Documents

Sales fell and losses deepened as regulatory and financing efforts remain in focus.

2025 saw lower sales and losses, but new funding and partnerships support future growth.

Sales fell on regulatory delays, but liquidity and patent position were strengthened.

Revenue guidance cut as sales lag and capital need grows amid delayed product launches.

Q1 sales up 45% and EBIT loss narrowed, with global expansion underway via new partnerships.

Exclusive Dräger deal and clinical validation position Monivent for global growth despite losses.

Sales fell and losses narrowed as Monivent pivots to global partnerships and secures new financing.

Regulatory advances and a global distribution deal position Monivent for commercial expansion.